Lataa...
An Avidity-based PD-L1 Antagonist Using Nanoparticle-Antibody Conjugates for Enhanced Immunotherapy
Upregulation of programmed death ligand 1 (PD-L1) allows cancer cells to evade antitumor immunity. Despite tremendous efforts in developing PD-1/PD-L1 immune checkpoint inhibitors (ICIs), clinical trials using such ICIs have shown inconsistent benefits. Here, we hypothesized that the ICI efficacy wo...
Tallennettuna:
| Julkaisussa: | Nano Lett |
|---|---|
| Päätekijät: | , , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7737517/ https://ncbi.nlm.nih.gov/pubmed/32510959 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acs.nanolett.0c00953 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|